Animal Or Plant Cell Patents (Class 424/93.7)
  • Patent number: 10373813
    Abstract: Mass spectra acquired by imaging mass spectrometry (IMS), in particular MALDI imaging of tissue sections, are each normalized by one of: the p-norm of the mass spectrum transformed by applying an exclusion list, the p-norm of the mass spectrum transformed by square rooting the intensity values, the median of the mass spectrum, and the median absolute deviation of the noise level of the mass spectrum.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: August 6, 2019
    Inventors: Soren-Oliver Deininger, Eryk Wolski
  • Patent number: 10373109
    Abstract: A first terminal determines a collection date of a somatic cell based on a desired collection date and a collectable date transmitted by a second medium; and outputs the collection date to a first medium. A second terminal outputs the collectable date to the second medium; and determines an acceptance date based on the collection date transmitted by the first medium and a production period of an iPS cell transmitted by a third medium. A third terminal determines the production period based on the collection date and a producible period, and determines a shipment date based on the production period and stockable location and period transmitted by a fourth medium; and outputs the production period to the third medium. A fourth terminal outputs the stockable location and period to the fourth medium; and determines stock location and period based on the production period and the stockable location and period.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: August 6, 2019
    Assignees: FANUC CORPORATION, I PEACE, INC.
    Inventors: Koji Tanabe, Kiyonori Inaba, Masaru Oda
  • Patent number: 10363275
    Abstract: The present invention relates to a method for isolating stem/progenitor cells from the amniotic membrane of umbilical cord, wherein the method comprises separating the amniotic membrane from the other components of the umbilical cord in vitro, culturing the amniotic membrane tissue under conditions allowing cell proliferation, and isolating the stem/progenitor cells from the tissue cultures. The isolated stem cell cells can have embryonic stem cell-like properties and can be used for various therapeutic purposes. In one embodiment, the invention relates to the isolation and cultivation of stem cells such as epithelial and/or mesenchymal stem/progenitor cells under conditions allowing the cells to undergo mitotic expansion. Furthermore, the invention is directed to a method for the differentiation of the isolated stem/progenitor cells into epithelial and/or mesenchymal cells.
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: July 30, 2019
    Assignee: CellResearch Corporation Pte Ltd
    Inventors: Toan-Thang Phan, Ivor Jiun Lim
  • Patent number: 10357519
    Abstract: The invention is in the field of regenerative medicine. It has been found that the conditioned medium of non-oval pluripotent liver progenitor cells exerts a tissue regenerating effect. A preparation of the cell free conditioned medium is therefore useful in the treatment of injury and organ failure, preferably liver and/or injury or failure.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: July 23, 2019
    Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Maria Beatriz Herrera Sanchez, Valentina Fonsato, Ciro Tetta, Giovanni Camussi
  • Patent number: 10354218
    Abstract: A system for an iPS cell bank includes a terminal and a server. The terminal receives and sends a production request including a desired collection date of a somatic cell and a customer ID to the server. The server stores a collectable date for collecting the somatic cell, a producible period for producing an iPS cell, and a location and a stockable period for stocking the iPS cell; and determines: a collection date based on the desired collection date and the collectable date; a production period based on the collection date and the producible period; an acceptance date of the somatic cell based on the collection date and the production period; a stock location and a stock period based on the production period, the stockable location, and the stockable period; and a shipment date of the iPS cell based on the production period, the stockable location, and the stockable period.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: July 16, 2019
    Assignees: FANUC CORPORATION, I PEACE, INC.
    Inventors: Koji Tanabe, Kiyonori Inaba, Masaru Oda
  • Patent number: 10336985
    Abstract: Provided is a method of inducing transdifferentiation of mesenchymal stem cells (MSC), the method including (a) culturing MSC in a first culture medium including a growth factor selected for allowing formation of neuralized MSC (NMSC); (b) allowing the NMSC to proliferate for a sufficient time during which said culture medium is renewed at least once; and (c) culturing the NMSC of (b) in a second culture media including cerebrospinal fluid (CSF) for a time sufficient for the NMSC to differentiate into a population of cells including terminally differentiated neurons, astrocytes and oligodendrocytes. Also provided by the present invention is the use of MSC or NMSC for providing a composition including said population and to kits including MSC or NMSC and instructions for use of same.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: July 2, 2019
    Assignee: Hadasit Medical Research Services & Development Limited
    Inventors: Dimitrios Karussis, Ibrahim Kassis
  • Patent number: 10335434
    Abstract: The present invention is directed to compositions and methods for treatment of ischemic diseases and conditions, particularly myocardial, CNS/brain and limb ischemia. More particularly, the present invention provides methods of treating disorders by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood, or bone marrow to an individual in need of treatment, wherein the drug is administered to the individual at a time point specifically determined to provide therapeutic efficacy. In one embodiment, the cells are for injection into ischemic myocardium for the treatment of angina.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: July 2, 2019
    Assignee: University of South Florida
    Inventors: Paul R. Sanberg, Alison E. Willing
  • Patent number: 10328102
    Abstract: The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum. Preferably the allogeneic serum has been determined as being negative for a serum tumor marker and/or an infectious factors, and the amount of the anticoagulant (e.g., heparin, a heparin derivative, or a salt thereof) added to the collected sample is less than 5 U/mL with respect to the volume of the sample or the amount of the anticoagulant in the medium at the start of culture is less than 0.5 U/mL. The present invention further relates to use of the method.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: June 25, 2019
    Assignee: SAPPORO MEDICAL UNIVERSITY
    Inventor: Osamu Honmou
  • Patent number: 10329529
    Abstract: Provided herein are placental stem cells that exhibit increased survival (“enhanced placental stem cells”), compositions comprising such placental stem cells, and methods of using such placental stem cells and compositions.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 25, 2019
    Assignee: CELULARITY, INC.
    Inventors: Stewart Abbot, Kathy Karasiewicz-Mendez, Xiaokui Zhang
  • Patent number: 10328535
    Abstract: A self-heating solder flux material includes a solder flux material and a multi-compartment microcapsule. The solder flux material includes a solvent carrier, and the multi-compartment microcapsule includes a first compartment, a second compartment, and an isolating structure. The first compartment contains a first reactant, and the second compartment contains a second reactant. The isolating structure separates the first compartment from the second compartment. The isolating structure is adapted to rupture in response to a stimulus. Rupture of the isolating structure results in an exothermic reaction between the first reactant and the second reactant. The exothermic reaction generates heat to volatilize the solvent carrier.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: June 25, 2019
    Assignee: International Business Machines Corporation
    Inventors: Eric J. Campbell, Sarah K. Czaplewski, Joseph Kuczynski, Timothy J. Tofil
  • Patent number: 10323074
    Abstract: The disclosure features, among other things, polypeptides comprising a Cryptic polypeptide, a functional fragment thereof, or variants of any of the foregoing. Also featured are nucleic acids encoding the polypeptides, methods for producing of the polypeptides, and a variety of diagnostic and therapeutic applications in which the polypeptides are useful. For example, the polypeptides can be used to treat a subject having a condition associated with bone loss.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: June 18, 2019
    Assignee: BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
    Inventors: Erik Martinez-Hackert, Senem Aykul
  • Patent number: 10314302
    Abstract: This disclosure describes a cryopreservative composition and methods for storing cells. Generally, the cryopreservative composition includes a sugar component and a sugar alcohol component, and is effective for storing and recovering cells without requiring dimethyl sulfoxide (DMSO).
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 11, 2019
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Allison Hubel, Kathryn Lindsay Pollock
  • Patent number: 10307442
    Abstract: A pharmaceutical composition for the prevention or treatment of a pulmonary disorder is provided. The composition contains mesenchymal stem cells showing improved proliferation and differentiation capacity which are characterized by the expression or non-expression of one or more particular cell markers. Also, provided is a method for obtaining mesenchymal stem cells showing improved proliferation and differentiation capacity based on the expression or non-expression of such cell markers. The mesenchymal stem cells having improved proliferation and differentiation capacity can be easily obtained from mesenchymal stem cells of various origins based on the expression or non-expression of CD26, CD49f, CD146 and EGFR. The mesenchymal stem cells thus obtained can be effectively used for the prevention or treatment of a pulmonary disorder such as, for example, pulmonary emphysema.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: June 4, 2019
    Assignee: MEDIPOST CO., LTD.
    Inventors: Yoon Sun Yang, Wonil Oh, Hye Jin Jin, Hong Bae Jeon, Miyeon Kim
  • Patent number: 10300090
    Abstract: The present disclosure provides distinct therapeutic populations of cells that form a pharmaceutical composition useful in hematopoietic stem/progenitor cell transplant. For example, the present disclosure provides a therapeutic population of cells, comprising an enriched population of hematopoietic stem/progenitor cells, memory T cells, regulatory T cells, and wherein the population of cells is depleted of naïve conventional ??-T cells. The present disclosure further provides methods of treatment using the therapeutic population of cells. In other embodiments, the present disclosure provides methods of producing a therapeutic population of cells.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: May 28, 2019
    Assignee: Orca Biosystems, Inc.
    Inventors: Ivan K. Dimov, Nathaniel Fernhoff, Kevin Sheehan
  • Patent number: 10294456
    Abstract: Disclosed is a method for culturing mesenchymal stem cells, comprising culturing mesenchymal stem cells in a medium containing calcium in a concentration of from 2.1 to 3.8 mM and magnesium in a concentration of from 1.0 to 3.0 mM under a hypoxic condition of 2 to 5% oxygen. The culturing method can increase the population of mesenchymal stem cells even with a small number of passages by improving mesenchymal stem cells in proliferative capacity and viability. In addition, the mesenchymal stem cells prepared by the culturing method are effectively used not only as a safe cell therapeutic agent due to their lacking immunogenicity, but also as a cartilage regenerating medicine owing to their excellent secretion of cytokines.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: May 21, 2019
    Assignee: MEDIPOST CO., LTD
    Inventors: Yoon-Sun Yang, Won Il Oh, Sun Jae Kwon, Mi Yeon Lee, Hong Bae Jeon
  • Patent number: 10293003
    Abstract: An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating chronic kidney disease that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a renal tissue regeneration mechanism by which Muse cells are made to selectively accumulate at a site of kidney disease and differentiate into cells that compose the kidney by administering Muse cells intravenously to a subject having the aforementioned disease.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: May 21, 2019
    Assignees: CLIO, INC., TOHOKU UNIVERSITY
    Inventors: Masanori Yoshida, Mari Dezawa
  • Patent number: 10294458
    Abstract: Provided herein are methods of differentiating stem cells via modulating miR-124, and the differentiated cells thereby. Also provided herein are methods for the treatment of diseases using the differentiated cells.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: May 21, 2019
    Assignee: ACCELERATED BIOSCIENCES CORP.
    Inventors: Jau-Nan Lee, Tony Tung-Yin Lee, Yuta Lee
  • Patent number: 10294264
    Abstract: Oxysterol-therapeutic agent derivatives or OXY133-therapeutic agent derivative compounds and methods of synthesizing the same are provided for use in promoting osteogenesis, osteoinduction and/or osteoconduction. Methods of synthesizing in a single container OXY133-therapeutic agent derivatives having high yields and improved process safety are also provided. Methods for synthesizing OXY133-therapeutic agent derivatives that are stereoselective are also provided.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: May 21, 2019
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Roger E. Harrington, Jerbrena C. Jacobs
  • Patent number: 10287588
    Abstract: Embodiment herein provide specially designed synthetic BCL11A-targeting microRNAs for RNA polymerase II expression, and methods of use to treat hemoglobinopathies such as sickle cell disease or thalassemia by increasing the expression levels of fetal hemoglobin levels. In particular illustrative embodiment, the present invention provides, in part, improved compositions and methods for achieving gene therapy in hematopoietic cells and hematopoietic precursor cells, including erythrocytes, erythroid progenitors, and embryonic stem cells. The invention further provides improved gene therapy methods for treating hematopoietic-related disorders.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: May 14, 2019
    Assignee: THE CHILDRENS'S MEDICAL CENTER CORPORATION
    Inventors: Michael Milsom, David A. Williams, Richard Gregory
  • Patent number: 10287553
    Abstract: There is provided a method for culturing a stem cell in vitro. The method comprises providing a substrate surface coated with a coating comprising a molecule having a catechol moiety or a polymer thereof; and growing a stem cell on said coated substrate surface in a growth medium.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: May 14, 2019
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Daniele Zink, Ming Ni, Karthikeyan Narayanan, Karthikeyan Kandasamy, Andrew C. A. Wan, Jackie Y. Ying
  • Patent number: 10286014
    Abstract: Simplification of a preparation step of a cell population used for the treatment of ischemic diseases, and provision of a cell population that shows more effective treatment are shown. A method of producing a cell population wherein a vascular endothelial progenitor cell and/or an anti-inflammatory macrophage are/is enriched, including cultivating a mononuclear cell derived from bone marrow, cord blood or peripheral blood in a serum-free medium containing stem cell factor, interleukin-6, FMS-like tyrosine kinase 3 ligand, thrombopoietin and vascular endothelial cell growth factor, and proliferating vascular endothelial progenitor cell from the cell; and a cell population obtained by the method are shown.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: May 14, 2019
    Assignees: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, TOKAI UNIVERSITY EDUCATIONAL SYSTEM, STEMMED INC., JUNTENDO EDUCATIONAL FOUNDATION
    Inventors: Takayuki Asahara, Haruchika Masuda, Rika Tanaka
  • Patent number: 10280400
    Abstract: A method of making retinal ganglion cells, comprises the steps of: (a) differentiating pluripotent stem cells into retinal progenitor cells; and, (b) differentiating retinal progenitor cells into retinal ganglion cells.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: May 7, 2019
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Sarah K. Ohlemacher, Jason S. Meyer
  • Patent number: 10281478
    Abstract: Ischemia is treated to prevent or manage disease by delivering stem cells derived from cord blood and/or tissue. A patient suffering from disease caused in at least some part by ischemia is selected. At least one dose consisting of an effective amount of stem cells is administrated through intravenous (IV), intra thecal, intra-arterial, via catheter into the organ, via Myostar catheter into the heart, intracoronary, intrapericardial, and/or by direct injection into the organ. Effectiveness of the administration is monitored at selected time periods to determine whether there exists an improved clinical indication. A second dose is administered by a method that is at least invasive as that utilized in the prior dose, and the steps are repeated until the clinical indication shows improvement or until there is contraindication to continued treatment. Diseases include at least one of Ischemia, arteriosclerosis, complications of ischemia, decreased perfusion, aging or diabetes.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: May 7, 2019
    Inventor: Wayne P. Franco
  • Patent number: 10272029
    Abstract: The present invention provides methods and compositions useful in the regeneration of damaged, lost and/or degenerated tissue in humans and animals. In certain embodiments, the present invention provides an acellular bioabsorbable tissue regeneration matrix, methods of making such a matrix, and methods of using such a matrix for the regeneration of damaged, lost and/or degenerated tissue. In certain embodiments, methods and compositions of the present invention are useful in the treatment of damaged, lost and/or degenerated nerve tissue.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: April 30, 2019
    Assignee: GENESIS TECHNOLOGIES LIMITED
    Inventor: Jan-Eric Ahlfors
  • Patent number: 10272118
    Abstract: The present invention relates to compositions and methods utilizing hair follicle derived Non-Bulbar Dermal Sheath cells for use in the treatment or prevention of the tendon injuries.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: April 30, 2019
    Assignee: RepliCel Life Sciences Inc.
    Inventors: Rolf Hoffmann, Kevin John McElwee
  • Patent number: 10266808
    Abstract: The present disclosure relates to compositions and methods comprising cell surface markers for hES-derived cells, in particular, endoderm lineage cells including pancreatic endoderm-type cells, derived from hES cells.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: April 23, 2019
    Assignee: ViaCyte, Inc.
    Inventors: Olivia Kelly, Anne Bang
  • Patent number: 10251917
    Abstract: This document provides methods and materials for treating a mammal (e.g., a human) having one or more tumors. For example, embolic agents including an amnion tissue preparation (e.g., amnion coated embolic agents) that can be used in arterial embolization to reduce or eliminate blood flow in a blood vessel that supplies a tumor are provided.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: April 9, 2019
    Inventor: Gary M. Petrucci
  • Patent number: 10253065
    Abstract: Provided herein are methods for the production of native and reconstituted hyaluronan (HA) complexes containing pentraxin-3 (PTX3) and heavy chain 1 (HC1) of inter alpha inhibitor (I?I). Compositions containing the complexes and therapeutic methods using the complexes are provided. Combinations and kits for use in practicing the methods also are provided.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: April 9, 2019
    Assignee: TISSUETECH, INC.
    Inventors: Scheffer Tseng, Hua He, Sean Tighe, Suzhen Zhang, Ying-Tieng Zhu
  • Patent number: 10246682
    Abstract: The production of high quality retinal pigmented epithelium (RPE) cells is necessary for research and potential therapeutic uses. Especially desirable are methods for the production of RPE cells using xeno-free culture conditions. Disclosed herein are novel methods for the production of RPE cells from pluripotent cells with high yields, including xeno-free production methods. Also provided are methods of efficiently isolating RPE cells from cultures containing heterogeneous cell types, allowing for substantially pure RPE cell cultures to be established. Additionally, novel methods for the cryopreservation of RPE cells are provided.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: April 2, 2019
    Assignees: The Regents of the University of California, University of Southern California
    Inventors: Dennis Clegg, Sherry T. Hikita, Lincoln V. Johnson, Liane Miller, Marlene Tsie, Chelsea D. Presbrey, Lisa R. Conti, Michelle A. Maloney, David R. Hinton, Qirui Hu
  • Patent number: 10246681
    Abstract: A method of transforming human cells into mechanosensory hair cells (MHCs), such as inner hear hair cells in the cochlea and vestibular organs, can include: causing human Wharton's jelly cells (hWJCs) to increase expression of or biological function of HATH1 so as to transform the hWJCs into MHCs. The method can include; administering a nucleic acid that encodes HATH1 to the hWJCs; causing inhibited expression of or biological function of HES1 and/or HES5 in the hWJCs; administering a nucleic acid that inhibits HES1 and/or a nucleic acid that inhibits HES5 to the hWJCs; causing inhibited expression of or biological function of HES1 and/or HES5 in the WJCs by administering a nucleic acid that inhibits HES1 and/or a nucleic acid that inhibits HES5; nucleic acids are administered includes a sequence of SEQ ID NO: 2, SEQ ID NO: 3, and/or SEQ ID NO: 4.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: April 2, 2019
    Assignee: The University of Kansas
    Inventors: Adam J Mellott, Michael Detamore, Hinrich Staecker
  • Patent number: 10246683
    Abstract: The present invention concerns a novel method and assembly for extraction of regenerative cellular components from an adipose tissue, the method comprising the steps of filtering a harvested adipose tissue for recovering its liquid fraction by means of a filtering element having a first cut-off value comprised between 40 microns and 70 microns; separating regenerative cellular components present in the liquid fraction by means of cell size segregation which blocks cells bigger than a second cut-off value ranging from 8 to 20 microns; and recovering the regenerative cells-rich fraction comprising the regenerative cellular components not having being blocked during the separating step.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: April 2, 2019
    Assignee: MyStem Limited
    Inventor: Piergiuseppe Ivona
  • Patent number: 10238692
    Abstract: Provided are a pharmaceutical composition for prevention and treatment of a neural disease including at least one selected from the group consisting of mesenchymal stem cells (MSCs), a culture solution of the MSCs, activin A, PF4, decorin, galectin 3, GDF15, glypican 3, MFRP, ICAM5, IGFBP7, PDGF-AA, SPARCL1, thrombospondin-1, WISP1, progranulin, IL-4, a factor inducing expression thereof, and any combination thereof, and a method therefor.
    Type: Grant
    Filed: November 16, 2009
    Date of Patent: March 26, 2019
    Assignee: MEDIPOST CO., LTD
    Inventors: Yoon-Sun Yang, Won II Oh, Jong Wook Chang, Ju Yeon Kim
  • Patent number: 10240124
    Abstract: The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein.
    Type: Grant
    Filed: September 19, 2012
    Date of Patent: March 26, 2019
    Assignee: BioLamina AB
    Inventors: Karl Tryggvason, Sergey Rodin
  • Patent number: 10233420
    Abstract: Described herein are methods of recellularizing an organ or tissue matrix.
    Type: Grant
    Filed: September 1, 2011
    Date of Patent: March 19, 2019
    Assignee: Regents of the University of Minnesota
    Inventors: Doris Taylor, Stefan M. Kren
  • Patent number: 10233422
    Abstract: Methods of generating cell lines with a sequence variation or copy number variation of a gene of interest, methods of use thereof, and cell lines with a sequence variation or copy number variation of a gene of interest are provided.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: March 19, 2019
    Assignees: PARKINSON'S INSTITUTE, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Renee Ann Reijo Pera, J. William Langston, Birgitt Schule, Theodore D. Palmer, Blake Byers, Ha Nam Nguyen, James Anthony Byrne, Branden John Cord
  • Patent number: 10226465
    Abstract: The present invention provides the new use of composition comprising at least one inhibitor of dipeptidyl peptidase IV (DPP-IV) for increasing migration and homing of haematopoetic progenitor cells in stem cell transplanted recipients, wherein said haematopoetic stem and/or progenitor cells had been treated in vitro with an engraftment enhancing compound, specifically with a prostacyclin analog and a cAMP enhancer before transplantation.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: March 12, 2019
    Assignee: SCIPHARM SÀRL
    Inventors: Michael Freissmuth, Eva-Maria Zebedin-Brandl, Zahra Kazemi
  • Patent number: 10213525
    Abstract: The invention provides a method for preparing a perfusion based islet cell containing extracellular matrix of liver, an islet cell recellularized extracellular matrix, and methods of using the recellularized matrix.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 26, 2019
    Assignee: Micromatrix Medical, Inc.
    Inventor: Jeffrey Ross
  • Patent number: 10213465
    Abstract: The current invention is a method and system for optimally isolating adult derived stem cells from whole blood and reintroducing the adult derived stem cells into a subject at specific target areas having damaged tissue to be repaired.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: February 26, 2019
    Inventors: Mark O'Neal Speight, Henry Edward Young
  • Patent number: 10213579
    Abstract: A catheter has a proximal portion of relatively larger central lumen diameter and outer diameter, and a distal portion of relatively smaller central lumen diameter and outer diameter, the two portions being integral with one another so that cells delivered into the central lumen of the proximal portion will flow through and exit the central lumen of the distal portion, encountering a constriction at the junction of the two portions, for infusion into body tissue at a predetermined target site when the catheter is inserted into a designated natural body vessel or duct leading to the target site. The cells are delivered in a fluid under pressure through a central lumen of the catheter to exit distally from the lumen at the target site, and meander of exiting fluid pressure from a predetermined value is minimized by adjusting the fluid pressure at the point of entry into the catheter's central lumen accordingly.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: February 26, 2019
    Assignee: SciCoTec GmbH
    Inventor: Eckhard U. Alt
  • Patent number: 10206954
    Abstract: The present disclosure concerns methods and compositions for differentiating cells, including adipose cells, into chondrocyte-like cells via in vitro, ex vivo, and/or in vivo mechanical strain. In particular aspects, adipose cells or re-differentiated adipose cells that are chondrocyte-like cells, are delivered to a joint or are shaped into cartilage. In some embodiments, the adipose cells may be delivered to a joint, such as an intervertebral disc, following which the cells differentiate into chondrocyte-like cells to treat dysfunction of cartilage therein, including to repair degenerated discs, for example. In certain aspects, the cells prior to delivery to the individual are managed in the absence of growth factors, in vitro mechanical strain, and/or matrix molecules, for example.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: February 19, 2019
    Assignee: SpinalCyte, LLC
    Inventor: Pete O'Heeron
  • Patent number: 10206951
    Abstract: The present disclosure provides a method for treating an inflammatory neurological disease comprising administering a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: February 19, 2019
    Assignee: MESOBLAST, INC.
    Inventor: Claude Bernard
  • Patent number: 10208126
    Abstract: The present invention pertains to novel antibodies capable of binding to CD26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and/or preventing Graft-versus-Host Disease (GvHD), for use in treating Aplastic Anemia and/or for use in promoting engraftment after haematopoietic stem cell transplantation. Furthermore, the present invention provides pharmaceutical compositions comprising at least one antibody of the present invention, as well as provides a kit of parts.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: February 19, 2019
    Assignee: ADIENNE Pharma & Biotech SA
    Inventor: Antonio Francesco Di Naro
  • Patent number: 10201588
    Abstract: Described herein are materials and methods for treating dyslipidemia in a mammalian subject in need thereof comprising administering a growth hormone-releasing hormone (GHRH) antagonist or variant thereof to the subject.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: February 12, 2019
    Assignees: UNIVERSITY OF MIAMI, AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
    Inventors: Maritza Romero-Lucas, Andrew Schally, Rudolf Lucas, Neal Weintraub
  • Patent number: 10201636
    Abstract: Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that are formed from acellular extracellular matrix (ECM). The cardiovascular prostheses comprise various compositions, such as ECM based compositions, and structures, such as particulate structures, mesh constructs, encasement structures, coated structures and multi-sheet laminate structures.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: February 12, 2019
    Assignee: CORMATRIX CARDIOVASCULAR, INC.
    Inventor: Robert G Matheny
  • Patent number: 10195233
    Abstract: Cells derived from postpartum placenta and methods for their isolation are provided by the invention. The invention further provides cultures and compositions of the placenta-derived cells. The placenta-derived cells of the invention have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: February 5, 2019
    Assignee: DePuy Synthes Products, Inc.
    Inventors: Anthony J. Kihm, Ian Ross Harris, Sanjay Mistry, Alexander M. Harmon, Darin J. Messina, Agnieszka Seyda, Chin-Feng Yi, Anna Gosiewska
  • Patent number: 10195644
    Abstract: An inkjet printing method, system, and computer-usable tangible storage device to print cells and biomaterials for three-dimensional cellular scaffolds and engineered skin grafts are disclosed. The process simultaneously deposits living cells, nutrients, growth factors, therapeutic drugs along with biomaterial scaffolds at the right time and location. This technology can also be used for the microvasculature fabrication using appropriate human microvascular endothelial cells and fibrin to form the microvasculature. When printing human microvascular endothelial cells in conjunction with the fibrin, the cells aligned themselves inside the channels and proliferated to form confluent linings. The 3D tubular structure was also found in the printed patterns. Simultaneously printing biological materials to form a three-dimensional cellular scaffold promotes human microvascular endothelial cell proliferation and microvasculature formation.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: February 5, 2019
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Thomas Boland
  • Patent number: 10190094
    Abstract: This invention provides methods of generating induced sensory neurons (iSNs) from non-neuronal cells such as fibroblasts. The invention also provides methods of using iSNs in various therapeutic or non-therapeutic applications, e.g., methods to identify agents or cellular modulations that enhance iSN formation from non-neuronal cells.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: January 29, 2019
    Assignee: The Scripps Research Institute
    Inventors: Joel W. Blanchard, Kevin T. Eade, Kristin Baldwin
  • Patent number: 10188686
    Abstract: The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: January 29, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Hiroaki Uchida, Justus B. Cohen, Joseph C. Glorioso, III, Paola Grandi
  • Patent number: 10188681
    Abstract: This invention relates to cellular-based therapies for increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. To provide these therapeutic effects, a non-proliferative allogeneic leukocyte population is contacted with another leukocyte population. The non-proliferative allogeneic leukocyte population is modified to bear on its surface a low-immunogenic biocompatible polymer so as to prevent pro-inflammatory allo-recognition with the latter leukocyte population. Cellular-based preparations and processes for achieving cellular therapy are also provided.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: January 29, 2019
    Assignee: CANADIAN BLOOD SERVICES
    Inventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
  • Patent number: 10174285
    Abstract: Provided is a method including providing a population of cells including a target type of differentiated cells having a pre-identified cytoskeletal profile and at least one cell selected from undifferentiated cells, differentiating cells and differentiated cells being different from the target type of differentiated cells; and incubating the population of cells with a cytotoxic agent, in an amount and for a time period effective to form a modified population of cells including predominantly or consisting essentially of the target type of differentiated cells. The pre-identified cytoskeletal profile can include the presence of class III ?-tubulin on neuronal cells and the population of cells includes neural cells and neuronal cells.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: January 8, 2019
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED
    Inventors: Sharona Cohen Evenram, Benjamin Reubinoff